Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India

Virology. 2021 Jun:558:13-21. doi: 10.1016/j.virol.2021.02.002. Epub 2021 Mar 5.

Abstract

India is one of the most affected countries by COVID-19 pandemic; but little is understood regarding immune responses to SARS-CoV-2 in this region. Herein we examined SARS-CoV-2 neutralizing antibodies, IgG, IgM, IgA and memory B cells in COVID-19 recovered individual from India. While a vast majority of COVID-19 recovered individuals showed SARS-CoV-2 RBD-specific IgG, IgA and IgM antibodies (38/42, 90.47%; 21/42, 50%; 33/42, 78.57% respectively), only half of them had appreciable neutralizing antibody titers. RBD-specific IgG, but not IgA or IgM titers, correlated with neutralizing antibody titers and RBD-specific memory B cell frequencies. These findings have timely significance for identifying potential donors for plasma therapy using RBD-specific IgG assays as surrogate measurement for neutralizing antibodies in India. Further, this study provides useful information needed for designing large-scale studies towards understanding of inter-individual variation in immune memory to SARS CoV-2 natural infection for future vaccine evaluation and implementation efforts.

Keywords: COVID-19; India; Memory B cells; Neutralizing antibodies; Receptor binding domain; SARS-CoV-2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Neutralizing / analysis*
  • Antibodies, Viral / analysis*
  • B-Lymphocytes* / cytology
  • B-Lymphocytes* / immunology
  • COVID-19 / epidemiology
  • COVID-19 / immunology*
  • Humans
  • Immunity, Humoral
  • Immunoglobulin Isotypes / analysis
  • India / epidemiology
  • Male
  • Middle Aged
  • Pandemics
  • Spike Glycoprotein, Coronavirus / immunology*
  • Young Adult

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Immunoglobulin Isotypes
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2